NASDAQ:THOR - Synthorx Stock Price, Forecast & News

Synthorx trades on the NASDAQ under the ticker symbol "THOR."

Synthorx Inc (NASDAQ:THOR) posted its earnings results on Tuesday, November, 5th. The medical instruments supplier reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.12. View Synthorx's Earnings History.

Synthorx is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Synthorx.

5 analysts have issued 12-month price targets for Synthorx's shares. Their forecasts range from $30.00 to $68.00. On average, they anticipate Synthorx's share price to reach $53.80 in the next year. This suggests that the stock has a possible downside of 20.9%. View Analyst Price Targets for Synthorx.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synthorx in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Synthorx.

Media stories about THOR stock have been trending extremely negative this week, InfoTrie reports. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Synthorx earned a news impact score of -4.0 on InfoTrie's scale. They also gave media headlines about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Synthorx.

Some companies that are related to Synthorx include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), IDEXX Laboratories (IDXX), Teleflex (TFX), Steris (STE), Hologic (HOLX) and Varian Medical Systems (VAR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Synthorx investors own include Pfizer (PFE), Editas Medicine (EDIT), EXACT Sciences (EXAS), NVIDIA (NVDA), Heron Therapeutics (HRTX), Intercept Pharmaceuticals (ICPT), Penske Automotive Group (PAG), Exxon Mobil (XOM), Advanced Micro Devices (AMD) and Eiger Biopharmaceuticals (EIGR).

(THOR) raised $100 million in an initial public offering on Friday, December 7th 2018. The company issued 9,100,000 shares at a price of $10.00-$12.00 per share. Jefferies, Leerink Partners and Evercore ISI acted as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager.

Synthorx's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include ARP Americas LP (1.48%), Goldman Sachs Group Inc. (0.78%), State Street Corp (0.49%), Chicago Capital Management LLC (0.46%), Credit Suisse AG (0.40%) and Magnetar Financial LLC (0.38%). Company insiders that own Synthorx stock include Orbimed Advisors Llc, Ra Capital Healthcare Fund Lp and Tighe Reardon. View Institutional Ownership Trends for Synthorx.

THOR stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Goldman Sachs Group Inc., Russell Investments Group Ltd. and First Trust Advisors LP. View Insider Buying and Selling for Synthorx.

THOR stock was acquired by a variety of institutional investors in the last quarter, including ARP Americas LP, Chicago Capital Management LLC, Credit Suisse AG, Magnetar Financial LLC, Oxford Asset Management LLP, Glazer Capital LLC, Fort Baker Capital Management LP and Bank of America Corp DE. Company insiders that have bought Synthorx stock in the last two years include Orbimed Advisors Llc, Ra Capital Healthcare Fund Lp and Tighe Reardon. View Insider Buying and Selling for Synthorx.

Shares of THOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of THOR stock can currently be purchased for approximately $67.99.

Synthorx has a market capitalization of $2.20 billion. The medical instruments supplier earns $-56,610,000.00 in net income (profit) each year or ($6.59) on an earnings per share basis. Synthorx employs 39 workers across the globe.View Additional Information About Synthorx.

The official website for Synthorx is http://www.synthorx.com/.

Synthorx's mailing address is 11099 North Torrey Pines Road Suite 190, La Jolla CA, 92037. The medical instruments supplier can be reached via phone at 858-750-4700 or via email at [email protected]